N4 Pharma continue to make good progress in understanding Nuvec in the oncology space

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced a further update on its recent pre-clinical study with TNF alpha.

On 13 June 2022 the Company provided an update that the Medicines Discovery Catapult study showed clear tumour suppression with 10ug of the TNF-alpha loaded onto Nuvec® which was a lower dose than used in the earlier studies.

Biochemical analysis of blood and tissue samples has now been completed. Testing confirmed that treatment with 10ug TNF-alpha loaded onto Nuvec® resulted in an increase in circulating plasma TNF-alpha levels.

Analysis also indicated that tissues including the liver and the tumour cells may have been responsible for the transfection with the TNF plasmid and subsequent release of TNF-alpha into the circulation to suppress the tumour.  

This study provides further data to better understand the mechanism that produced the tumour suppression. This data indicates the most appropriate use of Nuvec® in the oncology field will likely be to combine it with one or more nucleic acids alongside a targeting ligand to allow specific cancer cells to be targeted.

The posters resulting from the original oncology studies undertaken by Nanomerics have been presented at the CRS Annual Meeting in Montreal, Canada and are available to view on the Company’s website.

Nigel Theobald, Chief Executive Officer of N4 Pharma, commented:

“We continue to make good progress in understanding how Nuvec® can be used in the oncology space and this work, combined with the potential opening up of the siRNA market and the early data coming from UQ on their oral work, gives us a lot of material to further focus our route to commercial success.

“We will provide a further update of this along with our interim results.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    N4 Pharma

    More articles like this

    N4 Pharma

    N4 Pharma plans for commercialising Nuvec (VIDEO)

    N4 Pharma plc (LON:N4P) CEO Nigel Theobald chats to DirectorsTalk Interviews about its development plans for commercialising Nuvec. Nigel talks us through the update highlights, explains why companies working with siRNA are much more open to using novel delivery

    N4 Pharma

    N4 Pharma’s proof of concept work is extremely encouraging

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced an update on its current work programmes. Highlights: ·      Medicines Discovery Catapult study shows demonstrable suppression of tumour

    N4 Pharma

    N4 Pharma AGM to be held on 24 March 2022

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that the Company’s audited accounts for the year ended 31 December 2021, together with the notice of

    N4 Pharma

    N4 Pharma EPO patent granted for Nuvec

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that further to the Company’s announcement dated 11 February 2021 in which it was stated that the

    N4 Pharma

    N4 Pharma acceleration in understanding of the capabilities of Nuvec

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, has announced its unaudited interim results for the six months ended 30 June 2021. Highlights: ·      Continued strategy to focus on three

    N4 Pharma

    N4 Pharma current in vivo work streams due to commence with Evotec

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided a further update on its current in vivo work streams due to commence shortly with Evotec. As announced on

    N4 Pharma

    N4 Pharma Q&A: Good, strong, steady progress (LON:N4P)

    N4 Pharma’s Nigel Theobald discusses the Material Transfer Agreements, collaborating with more partners, the in vivo studies, how the work done under the MTA may negate the need for the Company to do its own proof of concept work and what investors can expect in the coming months in this exclusive interview with DirectorsTalk.

    No more posts to show